SIGN THE PETITION
For people living with rare cancers, every clinical trial is more than research; it’s a lifeline. Dedifferentiated liposarcoma (DDLPS) is an aggressive, treatment-resistant sarcoma with limited treatment options. When brigimadlin (BI 907828) began early clinical trials, it brought genuine hope to a community that rarely hears the word “promising.” Brigimadlin demonstrated tumor shrinkage and disease stability offering meaningful time without progression.
“For the first time, my scans didn’t get worse,” said one trial participant. “Brigimadlin gave me time to breathe.”
Last year Boehringer Ingelheim abruptly halted the program for not meeting trial endpoints. At the CTOS scientific conference in November of 2024, Phase 3 results presented showed that the objective response and disease control rates were numerically superior with brigimadlin versus doxorubicin. The drug had not actually failed patients — it had been stopped.
This single decision left patients and researchers with many questions nowhere to turn. No continuation studies. No licensing to outside partners. No plan for compassionate access. For those who had seen results, it felt like having the rug pulled out from under them.
The Brigimadlin Petition is a direct response to that silence — a unified call from patients, caregivers, and clinicians urging Boehringer Ingelheim to let the science continue. Every signature represents someone who believes that progress shouldn’t be shelved when it shows promise.
This is about more than one drug. It’s about preserving hope in rare cancers, where hope is already scarce.
Join us at brigimadlinpetition.org. Because every moment matters — and so does every voice.
